Patents by Inventor Russ P Carstens

Russ P Carstens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions using splicing regulatory proteins involved in tumor suppression
    Patent number: 9127078
    Abstract: Methods and compositions for diagnosis and prognosis of mammalian carcinoma or cancer derived from primary epithelial cells and tissue fibrosis are designed using newly identified epithelial cell-type specific splicing factors ESRP1 and ESRP2, which have roles in tumor suppression. Diagnostic reagents for the detection of these splicing factors in nucleotide or protein form are useful in such methods. Therapeutic compositions can provide epithelial cells with these factors to maintain FGFR2 and assist in suppressing metastasis. A high throughput splicing assay to identify compounds that change splicing events is described. RNCP1 is also identified as a splicing factor and a diagnostic for conditions characterized by inappropriate FGFR2-splicing.
    Type: Grant
    Filed: July 21, 2009
    Date of Patent: September 8, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Russ P. Carstens, Claude Warzecha, John Hogenesch, Trey Sato
  • METHODS AND COMPOSITIONS USING SPLICING REGULATORY PROTEINS INVOLVED IN TUMOR SUPPRESSION
    Publication number: 20110177967
    Abstract: Methods and compositions for diagnosis and prognosis of mammalian carcinoma or cancer derived from primary epithelial cells and tissue fibrosis are designed using newly identified epithelial cell-type specific splicing factors ESRP1 and ESRP2, which have roles in tumor suppression. Diagnostic reagents for the detection of these splicing factors in nucleotide or protein form are useful in such methods. Therapeutic compositions can provide epithelial cells with these factors to maintain FGFR2 and assist in suppressing metastasis. A high throughput splicing assay to identify compounds that change splicing events is described. RNCP1 is also identified as a splicing factor and a diagnostic for conditions characterized by inappropriate FGFR2-splicing.
    Type: Application
    Filed: July 21, 2009
    Publication date: July 21, 2011
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Russ P. Carstens, Claude Warzecha, John Hogenesch, Trey Sato
  • ALTERNATIVE SPLICING OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 MRNA IN PROSTATE CANCER
    Publication number: 20020009755
    Abstract: The present invention relates, in general, to prostatic cancer and, in particular, to a method of monitoring progression of prostate cancer and to a method of treating the disease.
    Type: Application
    Filed: December 17, 1999
    Publication date: January 24, 2002
    Inventors: Mariano A. Garcia-Blanco, Russ P Carstens